medicin
shortag
spread
european
countri
mani
case
unavail
medicin
product
substanti
impact
capabl
nation
healthcar
system
ensur
continu
care
shortag
origin
multifactori
caus
particular
due
supplyrel
factor
eg
manufactur
issu
regulatori
issu
logist
distribut
demandrel
one
eg
fluctuat
drug
demand
parallel
market
tender
price
reimburs
polici
howev
extraordinari
geopolit
event
eg
brexit
may
also
affect
medicin
avail
capabl
european
regulatori
author
stakehold
involv
pharmaceut
distribut
chain
healthcar
assist
servic
defin
suitabl
problemsolv
strategi
limit
year
fragment
european
regulatori
framework
start
lack
univoc
definit
medicin
shortag
ema
hma
joint
task
forc
releas
first
harmon
shortag
definit
european
econom
area
eea
guidanc
public
commun
manuscript
aim
review
current
european
regulatori
framework
medicin
shortag
support
activ
regul
manufactur
healthcar
profession
algorithm
also
propos
use
harmon
procedur
determin
shortageunavail
impact
public
health
ration
problemsolv
strategi
adopt
differ
set
medicin
shortag
risen
worldwid
strain
capabl
nation
healthcar
system
ensur
patient
access
pharmacolog
therapi
beck
et
al
jia
zhao
schwartzberg
et
al
resili
pharmaceut
distribut
chain
stakehold
vari
base
differ
factor
product
characterist
involv
countri
birhli
unavail
medicin
product
patient
due
supplyrel
factor
eg
manufactur
issu
regulatori
issu
logist
distribut
demandrel
one
eg
fluctuat
drug
demand
parallel
market
tender
price
reimburs
polici
moreov
extraordinari
geopolit
event
eg
brexit
coronaviru
diseas
outbreak
china
also
strong
influenc
resili
pharmaceut
chain
patient
access
therapi
even
global
player
control
research
product
medicin
product
activ
regulatori
author
still
base
nation
supran
ie
european
union
eu
framework
europ
capabl
regulatori
author
subject
involv
pharmaceut
distribut
chain
healthcar
assist
servic
defin
suitabl
problemsolv
strategi
limit
fragment
regulatori
framework
bochenek
et
al
de
weerdt
et
al
ema
hma
releas
first
harmon
shortag
definit
european
econom
area
eea
ema
hma
although
propos
definit
relev
market
author
holder
mah
regulatori
author
first
step
promot
commun
coordin
among
european
pharmaceut
stakehold
regul
profession
work
differ
nation
healthcar
system
improv
resili
shortag
howev
kaleidoscop
regulatori
framework
shortag
critic
factor
heterogen
nation
legisl
reimburs
price
polici
medicin
market
around
europ
limit
establish
solid
european
emerg
plan
solv
shortag
problem
consid
numer
factor
caus
shortag
univoc
problemsolv
strategi
establish
european
level
need
bigpharmaceut
market
germani
said
et
al
itali
di
giorgio
et
al
far
small
one
like
finland
heiskanen
et
al
moreov
excess
fragment
nation
regulatori
framework
may
caus
drug
shortag
relationship
price
polici
avail
medicin
product
known
dave
et
al
de
weerdt
et
al
consid
differ
reimburs
polici
member
state
price
medicin
product
may
vari
significantli
around
europ
context
export
drug
product
profit
market
eg
parallel
trade
frequent
cite
one
demandrel
caus
drug
shortag
de
weerdt
et
al
noteworthi
causeeffect
relationship
still
debat
aguiar
ernest
import
medicin
product
eu
extraeu
countri
also
common
strategi
mitig
advers
effect
sever
shortag
said
et
al
notabl
small
european
countri
might
profit
enough
mah
justifi
build
new
manufactur
site
market
medicin
product
context
justifi
public
health
reason
nation
regulatori
author
adopt
regulatori
pathway
speed
releas
market
author
eg
art
direct
therefor
make
medicin
avail
nation
market
otherwis
parallel
trade
possibl
solut
ensur
patient
access
treatment
exampl
besid
grant
nation
market
author
small
englishspeak
countri
like
malta
ensur
medicin
suppli
mainli
art
author
parallel
import
licenc
contribut
residu
need
less
farrugia
inde
applic
art
permit
mah
product
alreadi
author
englishspeak
eu
countri
eg
uk
ireland
easi
access
maltes
market
howev
brexit
ema
concurr
updat
european
regulatori
framework
might
worsen
delic
balanc
exampl
new
medicin
traceabl
system
introduc
eu
regul
eu
increas
cost
product
distribut
medicin
product
affect
econom
sustain
actor
involv
pharmaceut
suppli
chain
eg
mah
parallel
distributor
potenti
repercuss
patient
access
treatment
fragil
eu
countri
forese
especi
case
lowpric
medicin
product
eg
gener
current
situat
evid
strategi
may
differ
efficaci
shortag
mitig
accord
featur
european
countri
involv
consequ
ration
practic
shortag
emerg
plan
origin
stronger
cooper
among
european
countri
base
assess
proscon
balanc
supran
level
manuscript
aim
review
current
upgrad
european
regulatori
framework
medicin
shortag
propos
theoret
approach
determin
shortageunavail
impact
capabl
nation
healthcar
system
ration
problemsolv
strategi
adopt
function
lead
caus
shortag
eg
product
price
importationexport
approach
would
use
european
regulatori
author
harmon
metric
around
union
moreov
would
also
help
subject
involv
nation
pharmaceut
distribut
chain
healthcar
system
eg
manufactur
wholesal
hospit
pharmaci
insur
compani
region
healthcar
author
light
flexibl
enough
ration
riskassess
riskmanag
strategi
mitig
shortag
effect
differ
industri
healthcar
set
current
regulatori
framework
problem
till
ground
accord
articl
direct
mah
distributor
ensur
appropri
continu
suppli
pharmaci
author
person
meet
need
patient
differ
european
countri
temporari
perman
disrupt
suppli
occur
mah
notifi
compet
author
also
provid
inform
caus
art
direct
notif
made
less
two
month
interrupt
suppli
place
case
deadlin
extend
eg
month
itali
italian
republ
moreov
art
direct
leav
plenti
room
member
state
establish
appropri
measur
ensur
prompt
commun
among
stakehold
author
market
suppli
withdraw
medicin
product
togeth
reason
decis
base
absenc
specif
harmon
detail
guidanc
detect
notif
suppli
interrupt
european
level
regul
fragment
occur
nation
level
term
shortag
taken
differ
mean
around
europ
de
weerdt
et
al
french
legisl
defin
shortag
inabl
commun
hospit
pharmaci
deliv
drug
patient
within
hour
bocquet
et
al
germani
differ
word
use
identifi
drug
shortag
deliverylevel
ie
lieferengpass
compromis
patient
therapi
absenc
avail
therapeut
altern
ie
versorgungsengpass
said
et
al
itali
italian
medicin
agenc
aifa
distinguish
carenz
identifi
manufacturingrel
shortag
includ
also
caus
mah
voluntari
withdraw
temporari
perman
identifi
unavail
medicin
product
specif
geograph
area
due
ineffici
pharmaceut
distribut
chain
di
giorgio
et
al
fragment
also
evid
commun
strategi
adopt
differ
eu
member
state
bochenek
et
al
accord
survey
carri
ema
hma
eu
compet
author
publish
shortag
alert
healthcar
profession
patient
wherea
industri
regul
alert
recipi
case
ema
hma
gener
inform
ongoingexpect
shortag
publicli
avail
webaccess
catalogu
period
upgrad
commun
tool
also
use
eg
relev
organ
channel
press
releas
profession
medic
journal
tv
newslett
social
media
case
shortag
alert
share
nation
electron
patient
health
system
electron
prescrib
system
use
physician
pharmacist
howev
major
case
specif
criteria
set
nation
author
public
moreov
publish
data
vari
significantli
casebycas
countrybycountri
improv
confus
profession
patient
nation
european
level
light
signific
effort
implement
regulatori
framework
undertaken
european
author
singl
nation
point
contact
spoc
creat
facilit
share
inform
nationwid
medicin
shortag
coordin
emerg
plan
among
compet
nation
author
ema
multicountri
shortag
ema
scientif
committe
also
involv
write
harmon
recommend
healthcar
profession
ema
hma
releas
two
joint
guidelin
shortag
provid
recommend
improv
collabor
among
regulatori
author
stakehold
ema
hma
b
guidanc
detect
notif
shortag
medicin
product
market
author
holder
mah
union
eea
contain
first
harmon
definit
shortag
valid
eu
ema
hma
shortag
medicin
product
human
veterinari
use
occur
suppli
meet
demand
nation
level
accord
definit
unavail
medicin
product
classifi
shortag
mah
suppli
insuffici
fulfil
demand
specif
countri
overal
least
consequ
deliveryrel
issu
due
region
suppli
disrupt
ineffici
nation
redistribut
stock
explicitli
definit
leav
nation
author
plenti
room
establish
approach
prevent
unavail
issu
accord
new
regulatori
provis
mah
notifi
shortag
includ
impendinganticip
suppli
interrupt
regulatori
author
affect
european
countri
ema
medicin
product
authoris
centralis
procedur
moreov
mah
ask
provid
detail
inform
product
natur
time
shortag
avail
altern
medicin
product
popul
affect
shortag
risk
patient
safeti
reduct
treatment
access
annex
guidelin
inform
use
compet
author
triag
assess
shortag
risk
second
hmaema
guidelin
good
practic
guidanc
commun
public
medicin
avail
issu
aim
enhanc
align
european
commun
shortag
improv
awar
healthcar
profession
patient
cooper
among
european
stakehold
ema
hma
sever
key
recommend
provid
nation
author
publicli
avail
shortag
unavail
due
revocationcess
market
author
guidelin
state
exampl
nationwid
shortag
publish
systemat
list
easili
access
searchabl
public
eu
countri
shortag
inform
also
publicli
commun
quickli
possibl
ensur
continu
care
remain
access
least
six
month
shortag
resolut
ongoingexpect
shortag
systemat
list
report
detail
affect
medicin
product
shortag
durat
caus
adopt
mitig
strategi
advic
healthcar
profession
includ
potenti
altern
medicin
product
recommend
chang
clinic
practicein
use
medicin
best
commun
tool
select
base
shortag
graviti
highprofil
tool
eg
press
releas
prefer
sever
shortag
high
impact
public
health
follow
public
hmaema
guidelin
sever
european
stakehold
associ
releas
posit
paper
confirm
signific
concern
shortag
eu
propos
solut
overcom
critic
still
ground
regardless
hmaema
task
forc
intervent
may
organis
repres
patient
consum
healthcar
profession
public
health
advoc
stimul
european
commiss
identifi
factor
lead
medicin
shortag
provid
clear
transpar
inform
root
caus
variou
associ
decemb
european
associ
repres
manufactur
parallel
distributor
pharmaceut
fulllin
wholesal
industri
pharmacist
issu
posit
paper
state
view
root
caus
classif
provid
suggest
improv
european
cooper
prevent
shortag
impact
public
health
variou
associ
particular
highlight
need
find
collabor
solut
medicin
shortag
coordin
eu
nation
polici
commun
campaign
cooper
start
adopt
harmon
shortag
definit
ration
definit
risk
shortag
essenti
product
eu
moreov
also
underlin
import
improv
monitor
shortag
cooper
eu
establish
prioriti
rank
shortag
address
highrisk
medicin
product
effici
without
introduc
disproportion
initi
could
opposit
effect
one
intend
although
hmaema
guidelin
releas
repres
essenti
first
step
provid
harmon
solut
shortag
europ
propos
approach
seem
perfect
exampl
cooper
process
among
concern
nation
author
detail
sinc
systemat
procedur
inform
share
among
nation
spoc
provid
yet
ema
hma
b
moment
ema
decis
tree
specif
shortag
due
gmp
noncompliancequ
defect
publicli
avail
ema
moreov
procedur
triag
shortag
impact
patient
health
detail
guidelin
leav
plenti
room
member
state
defin
measur
assess
inform
notifi
mah
mitig
risk
shortag
howev
strong
need
proper
effect
riskassess
problemsolv
strategi
reduc
nationwid
shortag
without
wast
money
time
absenc
harmon
triag
procedur
risk
increas
workload
mah
regulatori
author
manag
shortag
low
impact
public
health
even
though
alreadi
mitig
manag
effect
dispens
level
report
royal
dutch
pharmacist
associ
platform
continu
treatment
ensur
medicin
shortag
case
medicin
substitut
therapeut
altern
pgeu
one
countri
involv
shortag
situat
even
critic
exampl
medicin
product
may
triag
differ
matter
compet
nation
author
differ
mitig
plan
may
requir
mah
hypothesi
particularli
relev
comarket
product
produc
contractor
medicin
product
author
decentr
mutual
recognit
procedur
involv
spoc
may
abl
assess
shortag
crisi
quickli
coordin
mitig
strategi
use
matter
consequ
effort
mahcontractor
restor
nation
suppli
may
slow
differ
nation
oblig
contrast
exampl
presenc
reduc
manufactur
capac
oblig
mah
maintain
prevent
stockpil
countri
eg
switzerland
may
worsen
product
avail
involv
market
anoth
critic
issu
adequ
tackl
guidelin
yet
manag
product
shortag
induc
raw
materi
unavail
inde
ongoingexpect
shortag
raw
materi
may
caus
rippl
effect
shortag
medicin
product
sever
countri
without
mah
predict
notifi
advanc
econom
global
promot
deloc
gather
manufactur
site
pharmaceut
raw
materi
impact
resili
pharmaceut
suppli
chain
mani
medicin
product
shortag
exampl
socal
great
acetonitril
shortag
caus
shortag
sever
drug
substanc
synthesi
solvent
use
drug
product
pda
sartan
immunoglobulin
give
exampl
former
case
discoveri
cancerogen
impur
sartan
ie
valsartan
losartan
irbesartan
produc
manufactur
blockag
drug
substanc
product
multipl
medicin
recal
caus
sever
shortag
european
countri
ema
latter
case
shortag
due
lowmanufactur
capac
comparison
grow
demand
immunoglobulin
although
immunoglobulin
use
tripl
worldwid
past
year
product
limit
avail
human
plasma
immunoglobulin
extract
purifi
carrock
sewel
et
al
context
sever
nation
author
eg
franc
germani
uk
publish
prioriti
rank
guidelin
use
immunoglobulin
clinic
practic
reduc
shortag
risk
ration
patient
access
therapi
case
notif
process
propos
emahma
guidelin
seem
suffici
detect
risk
shortag
sinc
mah
awar
resili
raw
materi
supplier
shortag
therefor
abl
monitor
effect
raw
materi
supplier
predict
failur
manufactur
chain
product
central
coordin
risk
control
strategi
ema
consequ
effici
share
inform
among
nation
regulatori
author
need
better
mitig
shortag
impact
nation
level
fulfil
need
patient
consid
critic
issu
latest
posit
paper
stakehold
associ
variou
associ
b
establish
harmon
metric
classifi
impact
medicin
shortag
nation
healthcar
system
mandatori
step
enhanc
cooper
among
compet
nation
author
european
countri
ration
effort
mitig
regul
profession
associ
propos
sever
systemat
measur
assess
shortag
problem
beck
et
al
bochenek
et
al
ema
jia
zhao
panzitta
et
al
pda
howev
propos
strategi
gener
design
face
specif
shortag
root
caus
eg
manufactur
failur
low
price
distributionproblem
strategi
appli
solv
shortag
type
communicationscooper
among
stakehold
may
limit
howev
end
exist
problemsolv
strategi
aim
face
issu
medicin
unavail
patient
increas
risk
health
phuong
et
al
consequ
estim
shortag
impact
patient
need
aspect
primari
harmon
exist
metric
ration
problemsolv
strategi
adopt
base
assumpt
propos
procedur
determin
impact
shortageunavail
healthcar
assist
therefor
patient
access
therapi
commun
strategi
adopt
fig
shortag
imagin
diseas
nation
healthcar
system
consequ
procedur
ideal
consid
shortageagainst
antibodi
two
part
form
antibodi
one
specif
antigen
variabl
region
bind
recognit
immun
system
constant
part
similarli
ideal
regulatori
procedur
compos
constant
part
recogn
eu
countri
stakehold
variabl
part
focus
shortag
caus
tackl
peculiar
nation
regulatori
framework
way
result
metric
allow
promot
one
hand
harmon
risk
assess
shortag
eu
level
hand
ration
prevent
manag
strategi
causespecif
matter
procedur
may
fulli
integr
exist
adopt
strategi
therefor
may
ad
valu
european
regulatori
author
subject
involv
nation
pharmaceut
distribut
chain
healthcar
system
eg
manufactur
wholesal
hospit
pharmaci
insur
compani
region
healthcar
author
inde
uniqu
triag
procedur
shortag
impact
improv
stakehold
cooper
manag
emerg
time
use
european
regulatori
author
assess
potenti
risk
shortag
medicin
product
sinc
obtain
market
author
allow
establish
prevent
action
improv
mah
resili
minim
risk
patient
health
moreov
procedur
also
adapt
appli
hospit
set
allow
pharmacist
identifi
medicin
product
stock
like
expos
risk
shortag
set
appropri
strategi
prevent
ineffici
healthcar
assist
caus
shortag
constant
part
algorithm
may
appli
ema
fig
scheme
harmon
procedur
tackl
drug
shortag
eu
um
musazzi
et
al
intern
journal
pharmaceut
consensu
hma
member
part
activ
hmaema
task
forc
hma
constant
part
algorithm
aim
provid
harmon
tool
evalu
impact
drug
shortag
clinic
demand
european
countri
consid
neg
effect
medicin
shortag
strongli
vari
accord
type
treat
diseas
realworld
patient
assess
therapi
procedur
assign
overal
score
shortag
impact
ie
high
medium
low
may
design
three
level
type
diseas
treat
ii
avail
therapeut
altern
iii
market
share
product
specif
countri
comparison
avail
altern
tabl
report
score
level
data
need
level
either
avail
compet
nation
author
includ
notif
mah
send
expectedongo
shortag
accord
guidelin
mah
ema
hma
level
type
diseas
treat
shown
fig
first
step
classifi
medicin
product
shortag
expectedongo
base
therapeut
indic
level
name
product
lifesupport
lifesustain
rare
diseas
b
product
sever
debilit
diseas
acut
chronic
c
product
diseas
shortag
lifesupport
medicin
product
result
higher
impact
patient
health
one
use
treat
nonseri
ill
allerg
rhiniti
score
assign
medicin
product
carri
adopt
principl
ven
vitalessentialnonessenti
analysi
approach
altern
indic
compet
nation
author
consid
much
essenti
medicin
may
indirectli
obtain
offici
document
provid
support
inclusionexclus
list
reimburs
medicin
inde
mani
european
countri
eg
itali
serious
diseas
one
relev
criteria
compet
nation
author
perform
health
technolog
assess
hta
two
medicin
product
contain
drug
substanc
atc
level
iii
therapeut
pharmacolog
subgroup
iv
chemicaltherapeuticpharmacolog
subgroup
b
two
medicin
product
atc
level
iii
atc
level
iv
c
two
medicin
product
contain
drug
substanc
atc
level
iv
gener
product
avail
atc
level
v
chemic
substanc
therapeut
moieti
two
gener
product
atc
level
v
iii
product
market
share
specif
countri
market
share
higher
annual
product
volum
market
share
annual
product
volum
market
share
lower
annual
product
volum
fig
determin
shortag
impact
patient
health
um
musazzi
et
al
intern
journal
pharmaceut
determin
elig
medicin
product
reimburs
exampl
medicin
product
consid
essenti
chronic
medicin
product
get
access
reimburs
aifa
assess
italian
republ
medicin
product
indic
treatment
sever
diseas
seriou
low
preval
consid
guarante
continu
care
fragil
patient
popul
serious
shortag
impact
public
health
also
influenc
exist
therapeut
altern
ensur
continu
care
pgeu
therefor
class
analys
assess
avail
therapeut
option
level
ii
fig
tabl
differ
score
assign
decreas
order
import
base
neg
impact
public
health
tabl
lower
number
therapeut
altern
market
higher
neg
effect
shortag
public
health
score
avail
treatment
two
medicin
product
contain
drug
substanc
atc
level
iii
therapeuticpharmacolog
subgroup
iv
chemicaltherapeuticpharmacolog
subgroup
b
two
medicin
product
atc
level
iii
atc
level
iv
c
two
medicin
product
contain
drug
substanc
atc
level
iv
gener
product
avail
atc
level
v
chemic
substanc
therapeut
moieti
two
gener
product
atc
level
v
noteworthi
avail
treatment
market
european
countri
medicin
product
consid
assess
obtain
market
author
place
market
mah
yet
moreov
medicin
neglig
market
share
lower
total
demand
refer
product
shortag
taken
account
well
sinc
neglig
impact
preserv
patient
access
therapi
differ
among
score
base
critic
associ
medicin
interchang
inde
expect
shortag
easili
mitig
avail
therapeut
equival
product
substitut
pharmaci
set
european
countri
wouter
et
al
two
medicin
product
therapeut
equival
contain
activ
substanc
therapeut
moieti
atc
level
v
clinic
show
efficaci
safeti
emea
gener
product
fall
class
contrari
unavail
gener
product
impli
best
scenario
benefitrisk
balanc
therapeut
interchang
evalu
physician
case
medicin
product
altern
atclevel
iii
eg
penicillin
vs
tetracyclin
iv
altern
eg
amoxicillin
vs
ampicillin
case
efficacysafeti
pattern
two
altern
may
therefor
substitut
automat
carri
commun
pharmacist
consequ
shortag
impact
potenti
higher
patient
expos
higher
risk
cure
discontinu
physician
promptli
access
exist
therapeut
altern
may
enough
mitig
neg
effect
medicin
shortag
inde
therapeut
altern
low
market
share
mah
suppli
enough
fulfil
patient
need
crisi
risk
shortag
lowmarketshar
altern
also
increas
rippl
effect
monopolist
market
medicin
product
higher
probabl
competitor
abl
sustain
patient
demand
shortag
inde
parson
colleagu
suggest
exist
invers
correl
number
supplier
antineoplast
drug
us
shortag
occurr
parson
et
al
regardless
presenc
therapeut
altern
market
lower
supplier
number
greater
number
drug
shortag
therefor
algorithm
level
iii
higher
market
share
medicin
express
annual
volum
comparison
exist
therapeut
altern
higher
potenti
risk
public
health
case
shortag
consequ
follow
score
empir
defin
tabl
market
share
higher
entir
nation
market
market
share
market
share
lower
score
b
c
level
ii
product
market
share
estim
concern
atc
level
iii
iv
product
includ
score
level
ii
leveliii
score
determin
comparison
product
includ
atc
level
v
base
score
obtain
constant
part
algorithm
decis
tree
riskmanag
strategi
ie
variabl
part
algorithm
built
accord
featur
differ
set
eg
manufactur
wholesal
hospit
pharmaci
nation
regulatori
framework
exampl
possibl
applic
variabl
part
algorithm
report
medicin
shortag
may
caus
blockag
product
differ
caus
eg
unavail
raw
materi
qualityfailur
gmp
nocompli
qualiti
defect
context
consider
effort
made
regulatori
author
profession
associ
improv
qualiti
pharmaceut
process
minim
risk
patient
improv
effect
manufactur
process
isp
pda
ema
variou
associ
exampl
ninefold
increas
ema
qualiti
guidelin
observ
mitig
risk
qualityfailur
ema
promot
applic
qualitybydesign
qualiti
risk
assess
principl
manufactur
medicin
product
ema
ema
b
ration
pharmaceut
manufactur
control
strategi
deriv
better
knowledg
product
process
tradit
qualiti
control
process
gener
base
test
critic
paramet
manufactur
step
impact
qualiti
intermedi
final
medicin
product
control
setpoint
oper
rang
therefor
fix
base
experi
carri
pharmaceut
develop
chang
notifiedauthor
regulatori
author
postapprov
chang
applic
modern
pharmaceut
qualiti
system
promot
systemat
continu
evalu
understand
refin
formul
manufactur
process
identif
critic
materi
attribut
process
paramet
determin
exist
function
relationship
factor
respons
ie
qualiti
profil
product
howev
effect
pharmaceut
qualiti
system
requir
close
collabor
mah
supplier
raw
materi
promot
ration
definit
critic
qualiti
attribut
drug
product
improv
product
resili
implement
qualiti
risk
manag
plan
includ
shortagespecif
prevent
manag
plan
propos
enhanc
resili
manufactur
shortag
isp
pda
panzitta
et
al
exampl
panzitta
cowork
propos
qualit
risk
assess
base
classif
differ
risk
factor
caus
shortag
manufactur
process
panzitta
et
al
base
result
risk
rank
manufactur
defin
proper
strategi
prevent
shortag
eg
increas
raw
materi
supplier
expans
materi
stock
howev
measur
may
appli
situat
sinc
high
impact
econom
sustain
exampl
mainten
larg
materi
stockpil
expans
supplier
number
rel
increas
inspect
audit
might
sustain
manufactur
lowpric
drug
product
consider
adopt
prevent
tool
propos
stakehold
associ
pda
isp
could
carri
gradual
mah
base
shortag
impact
product
treat
patient
econom
sustain
mah
product
context
propos
algorithm
appli
enforc
gradual
implement
pharmaceut
qualiti
system
mah
vulner
shortag
risk
shown
fig
oblig
mah
determin
base
shortag
impact
score
product
high
shortag
impact
establish
shortag
prevent
plan
seem
essenti
ensur
appropri
continu
suppli
fulfil
patient
need
product
manufactur
resili
improv
oner
provis
oblig
mah
qualifi
least
two
supplier
drug
substanc
stockpil
expans
implement
manufactur
technolog
risk
assess
tool
context
establish
ad
hoc
agreement
european
countri
mah
conduct
except
manufactur
activ
specif
nation
site
also
pursu
exampl
itali
nation
militari
manufactur
site
involv
activ
mitig
impact
sever
shortag
especi
case
old
lowcost
medicin
product
di
giorgio
et
al
side
shortag
impact
medicin
product
public
health
low
reason
charg
mah
addit
cost
therefor
affect
econom
sustain
implement
qualiti
assur
system
may
limit
posit
impact
continu
care
medicin
price
cite
among
caus
shortag
worldwid
jia
zhao
bochenek
et
al
heiskenen
et
al
de
weerdt
et
al
dave
et
al
inde
especi
lowpric
medicin
product
market
competit
may
affect
econom
sustain
mah
significantli
decreas
manufactur
capac
resili
demand
fluctuat
context
mah
may
abl
fulfil
appropri
guidanc
report
isp
drug
shortag
prevent
plan
suggest
last
hma
ema
guidelin
ema
hma
inde
especi
old
medicin
product
cost
upgrad
requir
highqual
standard
risk
assess
plan
may
high
maintain
mah
econom
sustain
context
european
associ
repres
manufactur
parallel
distributor
pharmaceut
fulllin
wholesal
industri
pharmacist
recent
stress
need
establish
proper
reward
action
compet
author
support
activ
compli
regul
upgrad
eg
falsifi
medicin
direct
variou
associ
applic
econom
incent
mah
propos
solut
prevent
shortag
exampl
jia
zhao
demonstr
price
increas
result
signific
reduct
risk
shortag
us
market
jia
zhao
howev
similar
approach
fulli
appli
eu
consid
fragment
european
price
reimburs
polici
econom
incent
mah
produc
medicin
product
provid
cutoff
regulatori
coststim
implement
qualiti
manufactur
process
improv
resili
product
blockag
feasibl
introduc
econom
incent
medicin
product
sinc
affect
budget
regulatori
author
gener
nation
healthcar
system
therefor
proper
harmon
decis
tree
design
appli
regulatori
incent
vulner
medicin
product
shortag
sinc
fee
time
dossier
variat
vari
significantli
among
european
regulatori
author
ega
extent
regulatori
incent
defin
priori
eulevel
calcul
percentag
current
fee
regulatori
time
adapt
differ
nation
set
fig
fig
show
hypothet
decis
tree
regulatori
incent
merg
shortag
impact
score
obtain
constant
part
algorithm
fig
product
price
latter
normal
realworld
market
share
inde
market
price
incent
impact
relev
lowvolum
medicin
product
highvolum
one
howev
jia
zhao
demonstr
jia
zhao
efficaci
regulatori
incent
prevent
shortag
also
link
creation
strengthen
failurestosuppli
claus
mah
reimburs
agreement
strategi
permit
improv
mah
sustain
ensur
proper
suppli
patient
demand
noteworthi
expect
provis
solv
econom
sustain
product
longterm
perspect
doubt
mitig
mah
situat
short
mediumterm
allow
adopt
proper
strategi
ration
product
improv
mah
sustain
medicin
product
affect
expectedongo
shortag
specif
countri
compet
nation
author
author
import
countri
eu
extraeu
ensur
patient
need
recent
survey
german
pharmacist
demonstr
commun
hospit
pharmaci
import
medicin
product
last
three
month
said
et
al
german
pharmacist
allow
import
medicin
product
presenc
order
specif
individu
patient
small
quantiti
product
ident
term
drug
substanc
compar
strength
avail
germani
therapeut
indic
section
medicin
product
act
arzneimittelgesetz
amg
european
countri
import
medicin
product
also
permit
import
obtain
formal
author
compet
nation
author
eg
itali
exampl
aifa
period
releas
portal
list
medicin
product
shortag
hospit
author
import
product
includ
list
august
aifa
unlik
aifa
list
medicin
product
shortag
item
aifa
importauthor
list
includ
medicin
product
therapeut
altern
avail
italian
market
regardless
procedur
requir
nation
level
medicin
import
case
uniqu
possibl
healthcar
profession
ensur
continu
care
patient
nation
therapeut
altern
avail
howev
excess
recours
parallel
import
european
countri
may
harm
medicin
unavail
one
rippl
effect
effect
may
worsen
uncontrol
medicin
movement
econom
reason
parallel
trade
art
treati
function
european
union
tfeu
di
giorgio
et
al
howev
art
tfeu
enabl
compet
nation
author
establish
prohibit
restrict
parallel
import
export
ground
protect
health
life
human
european
commiss
consequ
sever
european
countri
includ
specif
restrict
product
export
preserv
nation
stockpil
shortag
regulatori
framework
bochenek
et
al
howev
restrict
criteria
medicin
affect
shortag
harmon
eu
level
franc
poland
export
ban
appli
medicin
product
high
therapeut
valu
shortag
greec
ban
first
appli
vaccin
extend
medicin
product
shortag
spain
compet
author
restrict
export
medicin
product
therapeut
equival
itali
compet
author
adopt
combin
approach
prevent
export
could
worsen
product
shortagesunavail
one
side
aifa
start
prevent
verif
program
export
wholesal
distributor
detect
potenti
violat
good
distribut
practic
traceabl
rule
caus
abnorm
export
medicin
product
report
di
giorgio
et
al
pilot
verif
project
conduct
show
effect
reduc
distributionrel
unavail
specif
trace
product
di
giorgio
et
al
particular
adopt
counteract
measur
seem
effici
prevent
unavail
affect
commun
pharmaci
hospit
one
side
italian
regulatori
framework
updat
permit
aifa
impos
temporari
blockag
export
prevent
mitig
drug
shortag
unavail
medicin
product
author
itali
art
decreelaw
n
april
convert
law
n
june
moment
seven
medicin
product
ie
four
strength
levodopacarbidopa
cholestyramin
famotidina
famotidin
opicapon
includ
aifa
list
export
ban
aifa
case
list
includ
product
shortag
recent
end
distributionrel
unavail
itali
ie
product
contain
levodopacarbidopa
cholestyramin
inde
provis
aim
prevent
parallel
export
may
delay
wholesal
capabl
restor
suppli
italian
commun
hospit
pharmaci
postemerg
period
medicin
product
contain
opicapon
mg
capsul
famotidin
famotidina
mg
tablet
includ
prevent
purpos
medicin
product
contain
opicapon
use
treat
adult
parkinson
diseas
sinc
mah
commun
medicin
shortag
novemb
januari
manufactur
issu
export
ban
activ
aifa
prevent
medicin
deplet
nation
stock
could
affect
patient
access
therapi
famotidin
drug
substanc
atc
level
iv
ranitidin
avail
italian
market
detect
possibl
cancerogen
impur
ie
ndma
sever
batch
drug
substanc
ema
requir
massiv
withdraw
ranitidin
product
um
musazzi
et
al
intern
journal
pharmaceut
around
eu
ema
consequ
famotidin
demand
exceed
mah
product
capabl
run
avail
stock
context
export
ban
establish
aifa
aim
preserv
nation
product
stock
remov
long
possibl
onset
famotidin
shortag
establish
uniqu
decis
tree
support
nation
decis
medicin
importationexport
could
use
reduc
fragment
shortagemitig
strategi
among
european
countri
improv
effect
nation
strateg
plan
satisfi
patient
need
without
alter
nation
regulatori
framework
shown
fig
hypothet
decis
tree
may
link
possibl
import
block
export
shortag
impact
score
establish
constant
part
algorithm
fig
high
medium
impact
medicin
product
import
allow
ongo
shortag
case
highimpact
product
fast
author
procedur
also
adopt
speed
import
eu
parallel
import
extraeu
countri
similar
pharmaceut
qualiti
standard
eu
medicin
export
without
rippl
effect
side
may
conveni
case
lowshortageimpact
product
sinc
therapeut
altern
avail
nation
level
may
worsen
shortag
situat
european
countri
howev
import
medicin
product
alway
allow
except
case
substanti
reduct
nation
suppli
therapeut
equival
specif
patient
need
justifi
clinic
condit
eg
allergi
excipi
rare
metabol
diseas
moreov
similar
decis
tree
also
use
support
nation
compet
author
adopt
regulatori
pathway
art
direct
ensur
avail
medicin
specif
market
particularli
high
shortag
impact
public
health
blockagerestrict
export
feasibl
preventingmitig
strategi
specif
circumst
case
medicin
product
shortag
recent
end
suppli
lower
warm
level
adequ
fulfil
nation
demand
establish
export
ban
use
highimpact
product
sinc
mainten
nation
stock
directli
influenc
capabl
healthcar
system
ensur
patient
access
therapi
lowshortageimpact
product
strategi
may
restrict
provis
neglig
effect
continu
care
inde
therapeut
equival
medicin
product
substitut
therapeut
altern
without
compromis
safeti
patient
mediumshortageimpact
product
adopt
export
restrict
evalu
casebycas
base
avail
therapeut
option
moreov
promis
result
obtain
nation
compet
author
eg
aifa
suggest
set
cooper
scheme
administr
stakehold
foster
respons
approach
manag
crisi
medicin
suppli
also
allow
instanc
surveillanceverif
program
may
repres
ration
effect
prevent
strategi
monitor
activ
export
wholesal
distributor
reduc
risk
product
unavail
tool
strongli
necessari
highshortageimpact
product
adopt
prevent
action
monitor
mediumand
lowimpact
product
also
desir
howev
lowand
mediumimpact
product
develop
protocol
ration
clinic
medicin
substitut
activ
import
procedur
may
effect
context
educ
program
perform
compet
author
ensur
updat
healthcar
profession
topic
shortag
impact
score
calcul
constant
part
algorithm
use
improv
ration
commun
shortag
public
patient
recommend
better
commun
shortag
patient
introduc
last
hma
ema
guidelin
ema
hma
context
worth
underlin
commun
strategi
care
plan
base
level
shortag
critic
public
health
high
medium
low
without
doubt
patient
awar
shortag
import
aspect
compet
author
consid
everi
mitig
action
adopt
howev
essenti
avoid
alarm
patient
especi
therapeut
altern
promptli
avail
highprofil
commun
tool
eg
press
releas
social
network
televis
radio
um
musazzi
et
al
intern
journal
pharmaceut
prefer
commun
shortag
medicin
product
high
impact
score
wherea
drug
alert
healthcar
profession
patient
associ
suffici
product
medium
low
impact
score
moreov
shortageimpact
score
use
basi
harmon
graphic
format
commun
campaign
eu
countri
exampl
red
yellow
green
colour
use
systemat
nation
shortag
list
also
paper
commun
post
social
network
alert
softwar
use
physician
pharmacist
better
identifi
medicin
product
high
medium
low
impact
score
respect
econom
global
promot
deloc
gather
manufactur
site
drug
substanc
medicin
product
stress
resili
pharmaceut
suppli
chain
mani
medicin
product
shortag
european
countri
face
differ
shortag
crisi
alon
cooper
eulevel
necessari
provid
practic
ration
solut
problem
mitig
shortag
affect
union
stronger
coordin
eulevel
harmon
commun
riskassess
riskmanag
strategi
desir
urgent
although
studi
realworld
set
need
complet
valid
procedur
decis
tree
approach
propos
articl
may
contribut
improv
inform
share
cooper
among
european
countri
inde
riskassess
riskmanag
strategi
adopt
profession
eg
pharmacist
stakehold
ration
harmon
base
medicin
shortag
impact
score
calcul
compet
nation
author
moreov
structur
procedur
decis
tree
may
adapt
use
model
build
riskmanag
strategi
local
need
specif
healthcar
assist
set
eg
singl
hospit
howev
consid
shortageimpact
assess
link
author
therapeut
indic
medicin
product
procedur
propos
limit
latter
also
valid
shortagemitig
strategi
offlabel
use
medicin
product
specif
patient
popul
eg
paediatr
track
therefor
shortag
impact
may
assess
adequ
field
context
follow
exampl
provis
adopt
sever
nation
author
ensur
patient
access
immunoglobulin
treatment
eg
franc
germani
uk
establish
treatment
prioriti
rank
clinic
practic
guidelin
clinic
record
may
possibl
solut
activ
involv
ema
scientif
committe
consid
ad
valu
support
effort
compet
nation
author
parallel
cooper
among
regulatori
author
stakehold
pharmaceut
distribut
chain
also
improv
set
share
strategi
mitig
distributionrel
unavail
specif
geograph
region
prevent
shortag
context
establish
perman
consult
task
forc
group
desir
nation
european
level
speed
resolut
medicin
shortag
emerg
author
declar
follow
financi
interestsperson
relationship
may
consid
potenti
compet
interest
paola
minghetti
umberto
musazzi
conflict
interest
domenico
di
giorgio
state
scientif
public
impli
current
potenti
conflict
interest
administr
affili
view
opinion
express
coauthor
attribut
aifa
